CHINA GOVERNMENT INITIATIVES IN BIOTECHNOLOGY

February 2020
TABLE OF CONTENTS

1. What the Chinese government did to enhance competitiveness of its biotech industry 2
In this piece we discuss key government initiatives over the last decade to support budding Biotechnology sector as well as favorable external factors in private capital investments as well as talent pool.

In 2010, China’s State Council launched the Strategic Emerging Industries (SEI) Initiative, which identifies seven SEIs that the Chinese government feels are crucial to China’s economic competitiveness: energy efficient and environmental technologies, next generation IT, biotechnology, high-end equipment manufacturing, new energy, new materials, and new-energy vehicles. Development of these sectors is prioritized, and specific milestones have been declared.

As seen in the 13th FYP, it lays out the vision of China’s development over the years 2016-2020 and continues a theme of innovation as key to China’s growth. In it, goals for development of the biotechnology industry— an SEI— are provided, including the wide application of genomics; large-scale development of personalized medicine and new drugs; and the creation of gene and cell banks. As part of the 13th FYP, the Ministry of Science and Technology released a Biotechnology Development Plan which provides several goals and milestones to achieve with respect to China’s biotechnology industry by 2020 –

- **Enhance originality of biotechnology.** The plan directs the Chinese biotechnology industry to focus on developing new technologies and products. The mandate includes goals of developing 20-30 leading new technologies, 30-50 major strategic new products, and 5-80 key application-critical technologies.

- **Create a biotechnology innovation platform.** To accelerate the industrialization of biotechnology, the plan promotes construction of biotechnology innovation centers focusing on green bio-manufacturing, innovative drug R&D, and biomedical engineering.

- **Strengthen the industrialization of biotechnology.** It instructs to accelerate the construction of biotechnology specialized high-tech parks, including building 10-20 biopharmaceutical specialty parks and 5-10 bio-manufacturing specialty parks, each with an output value of over RMB10 billion.

The plan states that the scale of China’s biological industry should reach 8 to 10 trillion yuan ($1.2 to $1.6 trillion) by 2020.
MADE IN CHINA 2025

Made in China 2025 is an overarching government strategy document that outlines China’s plan to become a powerhouse in high-tech and high-value industries, such as robotics, advanced IT, aviation, and new energy vehicles, plus biopharmaceuticals and other medical technologies. Specifically for biotechnology, the roadmap includes specific goals for licensing of 3-5 new biotech drugs and their companion diagnostic reagents in advanced economies by 2020 plus commercialization of 30-35 innovative drugs (of all types) by 2025 as well as a broader goal of achieving world-class innovation capacity, production volume, and international competitiveness in pharmaceuticals by 2025.

BIOTECHNOLOGY PARKS

A major strategy to advance its biotechnology industry is building biotechnology parks. These large campuses are designed to collocate high-tech companies and are built around a common theme, such as biopharmaceuticals or nanotechnology. In addition to nationally created parks, nearly every province has a number of local bio-industry parks. Over 100 national level high-tech and economic industrial parks involving biotechnology and more than 400 provincial level biotech industrial parks exist across China so far. These parks provide infrastructure, talent pools, and business support for multiple collocated companies. For example, Suzhou Biobay in the Yangtze River Delta, provides nanotechnology service platforms for 51 companies, as well as offering support with regulatory filings and financing.
BUMPING UP REGULATORY BACKBONE

The National Medical Products Administration (NMPA) is the key regulator of drug approval and post-marketing supervision in China. The drug approval function is jointly overseen by three key entities under the NMPA:

- **The Center for Drug Evaluation (CDE)**, which takes the lead in assessing the efficacy and safety of new therapies. The technical review of clinical trial data is conducted at the CDE.

- **The National Institutes for Food and Drug Control (NIFDC)** is responsible for the registration test for an investigational drug’s samples, and the testing reports are sent to the CDE to facilitate the technical review.

- **The Center for Food and Drug Inspection (CFDI)** conducts onsite inspection of clinical trials and manufacturing facilities (i.e., GMP inspection) before the final approval of an investigational drug.

One of the key bottlenecks that has contributed to the slower drug approval process in China as been significant capacity constraints at the CDE, which had a staff of only about 100-120 people before 2015, vs. over 5,000 at the US Food and Drug Administration (FDA). One of the key reforms at the NMPA starting from 2015 has been the acceleration of talent recruitment, which we believe is the foundation for driving a more efficient drug approval system in China. In 2014-2018, the CDE’s headcount increased by about 7X and reached 800 in 2018, according to the Commissioner of the NMPA.

---

**HEADCOUNT AT THE CDE INCREASED BY 7X IN THE PAST THREE YEARS**

Source: NMPA, Goldman Sachs Research, 2018
Disclaimer

This document contains the opinions of Mirae Asset Global Investments (HK) Limited (“MAGIHK”) and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument and shall not constitute any form of regulated financial advice, legal, tax or other regulated service. Information contained herein has been obtained from sources believed to be reliable, but is not guaranteed. MAGIHK makes no representation as to their accuracy or completeness and therefore do not accept any liability for a loss arising from the use of this document.

All Investments contain risks. Forecasts, past information and estimates have certain inherent limitations. Statements concerning financial market trends or portfolio strategies are based on current market conditions, which will fluctuate. There is no guarantee that these opinions are suitable for all investors and each investor should evaluate their ability to invest for the long term, especially during periods of downturn in the market. Outlook and strategies are subject to change without notice.

Past performance is not a guarantee or a reliable indicator of future results. Before making any investment decision, investors should read the applicable fund prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the applicable investment and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice if in doubt.

This document is issued by MAGIHK (Licensed by the Securities and Futures Commission for Types 1, 4 and 9 regulated activities under the Securities and Futures Ordinance). This document has not been reviewed by the Securities and Futures Commission and no part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGI HK.

Copyright 2020. All rights reserved.